In Washington’s debate over enacting steep funding cuts to Medicaid, words are a central battleground.
FDA rejects Checkpoint Therapeutics’ PD-L1 drug cosibelimab over manufacturing issues
Checkpoint Therapeutics’ anti-PD-L1 antibody has been turned down by the FDA due to manufacturing issues, sending its share price down 45% premarket on Monday. The